Bernard and Irene Schwartz Center for Biomedical Imaging, Department of Radiology, New York University Grossman School of Medicine, New York, NY, USA.
Bernard and Irene Schwartz Center for Biomedical Imaging, Department of Radiology, New York University Grossman School of Medicine, New York, NY, USA; Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA.
Neuroimage Clin. 2023;37:103325. doi: 10.1016/j.nicl.2023.103325. Epub 2023 Jan 19.
Proton magnetic resonance spectroscopy (H MRS) offers biomarkers of metabolic damage after mild traumatic brain injury (mTBI), but a lack of replicability studies hampers clinical translation. In a conceptual replication study design, the results reported in four previous publications were used as the hypotheses (H1-H7), specifically: abnormalities in patients are diffuse (H1), confined to white matter (WM) (H2), comprise low N-acetyl-aspartate (NAA) levels and normal choline (Cho), creatine (Cr) and myo-inositol (mI) (H3), and correlate with clinical outcome (H4); additionally, a lack of findings in regional subcortical WM (H5) and deep gray matter (GM) structures (H6), except for higher mI in patients' putamen (H7).
26 mTBI patients (20 female, age 36.5 ± 12.5 [mean ± standard deviation] years), within two months from injury and 21 age-, sex-, and education-matched healthy controls were scanned at 3 Tesla with 3D echo-planar spectroscopic imaging. To test H1-H3, global analysis using linear regression was used to obtain metabolite levels of GM and WM in each brain lobe. For H4, patients were stratified into non-recovered and recovered subgroups using the Glasgow Outcome Scale Extended. To test H5-H7, regional analysis using spectral averaging estimated metabolite levels in four GM and six WM structures segmented from T1-weighted MRI. The Mann-Whitney U test and weighted least squares analysis of covariance were used to examine mean group differences in metabolite levels between all patients and all controls (H1-H3, H5-H7), and between recovered and non-recovered patients and their respectively matched controls (H4). Replicability was defined as the support or failure to support the null hypotheses in accordance with the content of H1-H7, and was further evaluated using percent differences, coefficients of variation, and effect size (Cohen's d).
Patients' occipital lobe WM Cho and Cr levels were 6.0% and 4.6% higher than controls', respectively (Cho, d = 0.37, p = 0.04; Cr, d = 0.63, p = 0.03). The same findings, i.e., higher patients' occipital lobe WM Cho and Cr (both p = 0.01), but with larger percent differences (Cho, 8.6%; Cr, 6.3%) and effect sizes (Cho, d = 0.52; Cr, d = 0.88) were found in the comparison of non-recovered patients to their matched controls. For the lobar WM Cho and Cr comparisons without statistical significance (frontal, parietal, temporal), unidirectional effect sizes were observed (Cho, d = 0.07 - 0.37; Cr, d = 0.27 - 0.63). No differences were found in any metabolite in any lobe in the comparison between recovered patients and their matched controls. In the regional analyses, no differences in metabolite levels were found in any GM or WM region, but all WM regions (posterior, frontal, corona radiata, and the genu, body, and splenium of the corpus callosum) exhibited unidirectional effect sizes for Cho and Cr (Cho, d = 0.03 - 0.34; Cr, d = 0.16 - 0.51).
We replicated findings of diffuse WM injury, which correlated with clinical outcome (supporting H1-H2, H4). These findings, however, were among the glial markers Cho and Cr, not the neuronal marker NAA (not supporting H3). No differences were found in regional GM and WM metabolite levels (supporting H5-H6), nor in putaminal mI (not supporting H7). Unidirectional effect sizes of higher patients' Cho and Cr within all WM analyses suggest widespread injury, and are in line with the conclusion from the previous publications, i.e., that detection of WM injury may be more dependent upon sensitivity of the H MRS technique than on the selection of specific regions. The findings lend further support to the corollary that clinic-ready H MRS biomarkers for mTBI may best be achieved by using high signal-to-noise-ratio single-voxels placed anywhere within WM. The biochemical signature of the injury, however, may differ and therefore absolute levels, rather than ratios may be preferred. Future replication efforts should further test the generalizability of these findings.
质子磁共振波谱(H MRS)提供了轻度创伤性脑损伤(mTBI)后代谢损伤的生物标志物,但缺乏复制性研究阻碍了其临床转化。在概念复制研究设计中,使用之前四项研究报告的结果作为假设(H1-H7),具体为:患者的异常表现为弥漫性(H1)、局限于白质(WM)(H2),包括低 N-乙酰天冬氨酸(NAA)水平和正常胆碱(Cho)、肌酸(Cr)和肌醇(mI)(H3),并与临床结果相关(H4);此外,亚皮质 WM(H5)和深部灰质(GM)结构(H6)中未发现异常,除了患者壳核的 mI 更高(H7)。
26 名 mTBI 患者(20 名女性,年龄 36.5±12.5[均值±标准差]岁),在损伤后两个月内,在 3 Tesla 上使用 3D 回波平面波谱成像进行扫描。为了测试 H1-H3,使用线性回归进行全局分析,以获得每个脑叶 GM 和 WM 的代谢物水平。对于 H4,使用格拉斯哥结局量表扩展将患者分为未恢复和恢复亚组。为了测试 H5-H7,使用光谱平均化的区域分析估计从 T1 加权 MRI 分割的四个 GM 和六个 WM 结构中的代谢物水平。Mann-Whitney U 检验和加权最小二乘协方差分析用于检查所有患者和所有对照组之间(H1-H3、H5-H7),以及恢复组和未恢复组患者与其各自匹配对照组之间(H4)的代谢物水平的平均组差异。可复制性定义为根据 H1-H7 的内容支持或不支持零假设,并进一步通过差异百分比、变异系数和效应量(Cohen's d)进行评估。
患者的枕叶 WM Cho 和 Cr 水平分别比对照组高 6.0%和 4.6%(Cho,d=0.37,p=0.04;Cr,d=0.63,p=0.03)。同样的发现,即患者枕叶 WM Cho 和 Cr 更高(均为 p=0.01),但差异百分比(Cho,8.6%;Cr,6.3%)和效应大小(Cho,d=0.52;Cr,d=0.88)更大,出现在未恢复患者与匹配对照组的比较中。对于无统计学意义的额叶、顶叶和颞叶 WM Cho 和 Cr 比较,观察到单向效应大小(Cho,d=0.07-0.37;Cr,d=0.27-0.63)。在恢复组和匹配对照组的比较中,在任何脑叶的任何代谢物中均未发现差异。在区域分析中,在任何 GM 或 WM 区域均未发现代谢物水平的差异,但所有 WM 区域(后、前、辐射冠和胼胝体的膝部、体部和压部)的 Cho 和 Cr 均表现出单向效应大小(Cho,d=0.03-0.34;Cr,d=0.16-0.51)。
我们复制了弥漫性 WM 损伤的发现,这些发现与临床结果相关(支持 H1-H2、H4)。然而,这些发现是在神经胶质标志物 Cho 和 Cr 中,而不是神经元标志物 NAA(不支持 H3)。在区域 GM 和 WM 代谢物水平(支持 H5-H6)中未发现差异,也未发现壳核 mI(不支持 H7)的差异。所有 WM 分析中患者 Cho 和 Cr 更高的单向效应大小表明广泛的损伤,这与之前出版物的结论一致,即 WM 损伤的检测可能更依赖于 H MRS 技术的灵敏度,而不是特定区域的选择。这些发现进一步支持了这样的推论,即 mTBI 的临床就绪型 H MRS 生物标志物可能最好通过在 WM 中的任何位置使用高信噪比单体素来实现。然而,损伤的生化特征可能不同,因此可能更喜欢绝对水平而不是比值。未来的复制研究应进一步测试这些发现的普遍性。